Regenerative biologics · graded by use, five uses
Exosome Therapy (extracellular vesicles)
Graded on: facial skin quality (instrument-measured surrogate; small split-face RCTs Randomized controlled trial: people are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect.).
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Corrected.
The headline said functional, the skin row said self-report and its note said surrogate; instrument readings are surrogate, and all three now say so. 'One randomized split-face trial' is corrected: Choi 2026 (PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 42403177) repeated Park 2023 (PMID 37377400) with the same product, funded and supplied by its maker, ExoCoBio, from the same group, so it is not independent replication, and Yen 2026 (PMID 42635327) and Park and Park 2026 (PMID 41752855) are independent but unblinded trials of different products. Huang 2026 (PMID 41800727) is described as n=6 in the ref as well as the note. Stack 2026 (PMID 41800726), which pooled mostly uncontrolled studies and contains no knee or systemic trial, no longer sits under the hair, knee or systemic rows. The hair row's search note now says Amini 2025 (PMID 40141845) lacks the publication-type tag the query relied on, and the knee row's Bolandnazar 2024 (PMID 39465400) is described in full. Letters unchanged; the hair hold is on the decision sheet.PMID 42403177 PMID 37377400 PMID 42635327 PMID 41752855 PMID 41800727 PMID 41800726 PMID 40141845 PMID 39465400
The hair row held a single D Route 1 while disclosing Amini et al. (Life (Basel), 2025; PMID 40141845), a randomized saline-controlled trial in 20 men whose plant-extract exosome formulation raised hair count against saline. Under the written rule a single positive randomized trial is C, but a C on a row named for exosome therapy would read as a C for the human stem-cell-derived products clinics sell, which no randomized trial has tested. The row is therefore split: the plant-derived formulation tested is C on one trial, and human stem-cell-derived exosomes for hair stay D Route 1 with their own absence check. The review hold on the hair row is closed. Decided October 2026 by editor adjudication (Arnold Sandlow, D.C.).PMID 40141845
Every change to a letter on this site is dated and published. The full evidence log →
Exosomes are tiny particles released by cells. In small studies, an exosome solution applied to the face after skin treatments improved measured skin quality. The second study was paid for by the maker. For hair loss, the stem cell products that are sold have not been shown to work. No study supports injecting exosomes into the blood for anti-aging.
The C is shared by two of the five uses graded on this record, each on its own evidence. The other three carry their own letters.
As studied, and the trials
Park et al. (J Cosmet Dermatol, 2023; PMID 37377400) randomized 28 subjects in a split-face design, three sessions over 12 weeks, and measured with PRIMOS, Cutometer and Corneometer rather than by eye. Choi et al. (J Microbiol, 2026; PMID 42403177) repeated the design in 16 adults with the same product, funded and supplied by its maker, ExoCoBio, from the same group; not independent replication. Yen et al. (J Craniofac Surg, 2026; PMID 42635327), 60 adults, unblinded, a different topical preparation after radiofrequency microneedling, wrinkle score 3.3 points better than microneedling alone at 12 weeks. Park and Park (Life, 2026; PMID 41752855), 75 patients, exosome boosters with laser for scars and skin quality, numerically better. Huang et al. (Aesthet Surg J, 2026; PMID 41800727) is n=6 and calls itself preliminary. Stack et al. (PMID 41800726) pooled 39 mostly uncontrolled studies and graded its own work Level of Evidence 3. C: several small split-face trials of different products, mostly unblinded, with instrument-measured surrogate endpoints A lab value or measurement used in place of the outcome that matters, such as LDL cholesterol standing in for heart attacks. Moving a surrogate does not always move the outcome., which cap this at B regardless of how many more appear.
As studied, and the trials
Amini et al. (Life (Basel), 2025; PMID 40141845): randomized saline-controlled trial, 20 men with Norwood 2 to 3 androgenetic alopecia, an exosome formulation containing Ecklonia cava and Thuja orientalis extracts or saline, four scalp sessions over eight weeks, hair count at week 16; hair count rose in the treated group and not on saline (between-group p = 0.006, large effect), no adverse events, authors declare no conflicts. One small positive randomized trial, unreplicated: C. This row grades the plant-derived formulation tested; it says nothing about the human stem-cell-derived exosome products sold for hair, which have their own row below.
As studied, and the trials
No randomized trial of human stem-cell-derived exosomes for hair growth has been found. The one randomized hair trial (Amini 2025, PMID 40141845) tested a plant-extract formulation and is graded on its own row. The 13 hair studies pooled by Stack 2026 are uncontrolled. Route 1: the product class that clinics sell for hair has not been tested in a randomized trial.
As studied, and the trials
Tested and no benefit. Bolandnazar et al. (BMC Musculoskelet Disord, 2024; PMID 39465400) was a triple-blind placebo-controlled trial in 31 patients with bilateral knee osteoarthritis, one knee injected with placental stromal cell-derived extracellular vesicles and the other with saline; no difference in pain, WOMAC, Lequesne or MRI at 2 and 6 months. This is among the most heavily marketed indications.
As studied, and the trials
No randomized trial exists for the use that is actually sold. Intravenous exosome infusion is offered commercially for aging, energy and recovery. Nothing randomized supports any of it. This is the gap between what the biology suggests and what has been tested, and it is the whole reason this entry exists.
Read the grade that matches your goal. How EBL grades by use →
A letter describes the human evidence, not the product, the manufacturer, or the intervention's worth.
See the full evidence record →Graded on Facial skin quality (instrument-measured surrogate; small split-face RCTs).
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on instrument-measured facial skin quality, from small randomized split-face trials: 28 subjects, an adipose stem cell exosome solution with microneedling against saline (Park et al., 2023; PMID 37377400), repeated in 16 adults with the same product and the maker's funding (Choi et al., 2026; PMID 42403177). Other uses carry their own letters: knee osteoarthritis is D, tested and null (PMID 39465400); hair growth is C for one small, unreplicated trial of a plant-derived formulation (PMID 40141845) and D for the human stem-cell-derived products sold for hair, which have no randomized trial.
WHAT THIS GRADE DOES NOT COVERintravenous or systemic infusion for aging, the use that is sold, for which no randomized trial exists. There are no FDA-approved exosome products.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Each use, with its trials
This record carries a separate letter for each thing it has been measured on. The headline grade is the best of them, and it does not transfer to the others.
Park et al. (J Cosmet Dermatol, 2023; PMID 37377400) randomized 28 subjects in a split-face design, three sessions over 12 weeks, and measured with PRIMOS, Cutometer and Corneometer rather than by eye. Choi et al. (J Microbiol, 2026; PMID 42403177) repeated the design in 16 adults with the same product, funded and supplied by its maker, ExoCoBio, from the same group; not independent replication. Yen et al. (J Craniofac Surg, 2026; PMID 42635327), 60 adults, unblinded, a different topical preparation after radiofrequency microneedling, wrinkle score 3.3 points better than microneedling alone at 12 weeks. Park and Park (Life, 2026; PMID 41752855), 75 patients, exosome boosters with laser for scars and skin quality, numerically better. Huang et al. (Aesthet Surg J, 2026; PMID 41800727) is n=6 and calls itself preliminary. Stack et al. (PMID 41800726) pooled 39 mostly uncontrolled studies and graded its own work Level of Evidence 3. C: several small split-face trials of different products, mostly unblinded, with instrument-measured surrogate endpoints, which cap this at B regardless of how many more appear.
Amini et al. (Life (Basel), 2025; PMID 40141845): randomized saline-controlled trial, 20 men with Norwood 2 to 3 androgenetic alopecia, an exosome formulation containing Ecklonia cava and Thuja orientalis extracts or saline, four scalp sessions over eight weeks, hair count at week 16; hair count rose in the treated group and not on saline (between-group p = 0.006, large effect), no adverse events, authors declare no conflicts. One small positive randomized trial, unreplicated: C. This row grades the plant-derived formulation tested; it says nothing about the human stem-cell-derived exosome products sold for hair, which have their own row below.
No randomized trial of human stem-cell-derived exosomes for hair growth has been found. The one randomized hair trial (Amini 2025, PMID 40141845) tested a plant-extract formulation and is graded on its own row. The 13 hair studies pooled by Stack 2026 are uncontrolled. Route 1: the product class that clinics sell for hair has not been tested in a randomized trial.
Tested and no benefit. Bolandnazar et al. (BMC Musculoskelet Disord, 2024; PMID 39465400) was a triple-blind placebo-controlled trial in 31 patients with bilateral knee osteoarthritis, one knee injected with placental stromal cell-derived extracellular vesicles and the other with saline; no difference in pain, WOMAC, Lequesne or MRI at 2 and 6 months. This is among the most heavily marketed indications.
No randomized trial exists for the use that is actually sold. Intravenous exosome infusion is offered commercially for aging, energy and recovery. Nothing randomized supports any of it. This is the gap between what the biology suggests and what has been tested, and it is the whole reason this entry exists.
The evidence, in fullEight papers, each linked to its PubMed record.
Skin: Park et al. (J Cosmet Dermatol, 2023; PMID 37377400): randomized split-face trial, 28 subjects, an adipose stem cell exosome solution with microneedling against saline with microneedling, three sessions over 12 weeks; wrinkles, elasticity, hydration and pigmentation measured by instrument; funded by the National Research Foundation of Korea. Choi et al. (J Microbiol, 2026; PMID 42403177): split-face randomized trial, 16 adults, the same adipose stem cell exosome product delivered by ultrasound against saline; water loss fell and hydration and elasticity rose; the product's maker, ExoCoBio, supplied it and funded the study, and the authors overlap with Park 2023, so this is the same group, not independent replication. Yen et al. (J Craniofac Surg, 2026; PMID 42635327): unblinded split-face randomized trial, 60 adults, a topical extracellular vesicle preparation after radiofrequency microneedling against microneedling alone; wrinkle score improved 3.3 points more at 12 weeks; no conflicts reported. Park and Park (Life, 2026; PMID 41752855): 75 patients with postoperative facial scars randomized to laser alone or laser with human-derived or plant-derived exosome boosters; numerically greater short-term scar and skin-quality improvement, human and plant products comparable; hospital-funded. Huang et al. (Aesthet Surg J, 2026; PMID 41800727): six-subject preliminary split-face study of rose stem cell exosomes after needling radiofrequency. Stack et al. (Aesthet Surg J, 2026; PMID 41800726): pooled 39 mostly uncontrolled studies, 20.2 percent wrinkle reduction, and rated its own work Level of Evidence 3; it contains no knee or systemic trial and supports nothing beyond the fact that studies exist. Knee: Bolandnazar et al. (BMC Musculoskelet Disord, 2024; PMID 39465400): triple-blind placebo-controlled trial, 31 patients, each with one knee injected with placental stromal cell extracellular vesicles and the other with saline; no difference in pain, function or MRI at 2 and 6 months. Hair: Amini et al. (Life, 2025; PMID 40141845): randomized saline-controlled pilot, 20 men, a plant-derived exosome formulation, more hair growth; not indexed under the randomized trial publication type. Grade C on skin: small split-face trials with instrument-measured surrogate endpoints, mostly unblinded, of different products.
This intervention remains investigational with no standardized clinical protocol. If enrolled in a formal protocol, track the primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight. defined by that protocol at the specified intervals. Source, dosing, and route of administration are consistent with any published protocol used as a reference.
Evidence notes: randomized trial
Endpoint graded: Facial skin quality (instrument-measured surrogate; small split-face RCTs) (surrogate)
Last reviewed: July 2026
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Primary evidenceEight papers, each linked to its PubMed record.
Skin: Park et al. (J Cosmet Dermatol, 2023; PMID 37377400): randomized split-face trial, 28 subjects, an adipose stem cell exosome solution with microneedling against saline with microneedling, three sessions over 12 weeks; wrinkles, elasticity, hydration and pigmentation measured by instrument; funded by the National Research Foundation of Korea. Choi et al. (J Microbiol, 2026; PMID 42403177): split-face randomized trial, 16 adults, the same adipose stem cell exosome product delivered by ultrasound against saline; water loss fell and hydration and elasticity rose; the product's maker, ExoCoBio, supplied it and funded the study, and the authors overlap with Park 2023, so this is the same group, not independent replication. Yen et al. (J Craniofac Surg, 2026; PMID 42635327): unblinded split-face randomized trial, 60 adults, a topical extracellular vesicle preparation after radiofrequency microneedling against microneedling alone; wrinkle score improved 3.3 points more at 12 weeks; no conflicts reported. Park and Park (Life, 2026; PMID 41752855): 75 patients with postoperative facial scars randomized to laser alone or laser with human-derived or plant-derived exosome boosters; numerically greater short-term scar and skin-quality improvement, human and plant products comparable; hospital-funded. Huang et al. (Aesthet Surg J, 2026; PMID 41800727): six-subject preliminary split-face study of rose stem cell exosomes after needling radiofrequency. Stack et al. (Aesthet Surg J, 2026; PMID 41800726): pooled 39 mostly uncontrolled studies, 20.2 percent wrinkle reduction, and rated its own work Level of Evidence 3; it contains no knee or systemic trial and supports nothing beyond the fact that studies exist. Knee: Bolandnazar et al. (BMC Musculoskelet Disord, 2024; PMID 39465400): triple-blind placebo-controlled trial, 31 patients, each with one knee injected with placental stromal cell extracellular vesicles and the other with saline; no difference in pain, function or MRI at 2 and 6 months. Hair: Amini et al. (Life, 2025; PMID 40141845): randomized saline-controlled pilot, 20 men, a plant-derived exosome formulation, more hair growth; not indexed under the randomized trial publication type. Grade C on skin: small split-face trials with instrument-measured surrogate endpoints, mostly unblinded, of different products.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale. Products listed under this modality may be commercial partners, and their purchase links may earn EBL a commission. Those products carry no letter of their own, every relationship is disclosed beside the link, and where a product does not deliver what the trials tested, this page says so regardless of who pays.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
How EBL searched for the trials (2 searches)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(exosome*[tiab] OR "extracellular vesicle*"[tiab]) AND (skin[tiab] OR facial[tiab] OR rejuvenation[tiab]) AND (randomized[tiab] OR "split-face"[tiab])("extracellular vesicle*"[tiab] OR exosome*[tiab]) AND (knee[tiab] OR osteoarthritis[tiab]) AND (randomized[tiab] OR randomized controlled trial[pt])Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →